Vimarsana
Biggest News Aggregation in the World

Page 3 - Briggs Morrison News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Briggs Morrison. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Briggs Morrison Today - Breaking & Trending Today

Syndax Pharmaceuticals (NASDAQ:SNDX) Receives New Coverage from Analysts at StockNews.com - Vimarsana News

Syndax Pharmaceuticals (NASDAQ:SNDX) Receives New Coverage from Analysts at StockNews.com

StockNews.com started coverage on shares of Syndax Pharmaceuticals (NASDAQ:SNDX – Free Report) in a research report sent to investors on Thursday. The firm issued a sell rating on the stock. A number of other research firms have also commented on SNDX. B. Riley raised their price objective on shares of Syndax Pharmaceuticals from $34.00 to […]

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Director Briggs Morrison Sells 52,855 Shares of Stock - Vimarsana News

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Director Briggs Morrison Sells 52,855 Shares of Stock

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Get Free Report) Director Briggs Morrison sold 52,855 shares of the firm’s stock in a transaction on Wednesday, August 9th. The shares were sold at an average price of $18.27, for a total transaction of $965,660.85. Following the completion of the transaction, the director now directly owns 17,836 shares of […]

Syndax Pharmaceuticals (NASDAQ:SNDX) Hits New 1-Year Low at $19.14 - Vimarsana News

Syndax Pharmaceuticals (NASDAQ:SNDX) Hits New 1-Year Low at $19.14

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Get Free Report) shares reached a new 52-week low on Monday . The stock traded as low as $19.14 and last traded at $19.20, with a volume of 34822 shares traded. The stock had previously closed at $19.76. Analyst Upgrades and Downgrades Several research firms have recently weighed in on […]

Arvinas Reports Second Quarter 2023 Financial Results and Provides Corporate Update - Vimarsana News

Arvinas Reports Second Quarter 2023 Financial Results and Provides Corporate Update

– Enrollment continues globally in multiple clinical studies of vepdegestrant , including VERITAC-2 2L Phase 3 trial and study lead-in for the VERITAC-3 1L Phase 3 trial, both in ER+/HER2-...

Syndax Pharmaceuticals (NASDAQ:SNDX) Issues Earnings Results - Vimarsana News

Syndax Pharmaceuticals (NASDAQ:SNDX) Issues Earnings Results

Syndax Pharmaceuticals (NASDAQ:SNDX – Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($0.64) EPS for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.09, Briefing.com reports. During the same quarter last year, the business posted ($0.62) EPS. Syndax Pharmaceuticals Stock Down 2.9 % SNDX traded down $0.59 during midday […]